Daiichi-Sankyo
Daiichi-Sankyo pays $39m to settle allegations
January 12, 2015Sales and Marketing Azor, Benicar, Daiichi Sankyo, Daiichi-Sankyo, Tribenzor, Welchol, kickbacks, us justice
Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Daiichi-Sankyo cleared of rep misconduct
November 22, 2010Medical Communications, Sales and Marketing ABPI, ABPI Code of Practice, Daiichi Sankyo, Daiichi-Sankyo, Olmetec, PMCPA, olmesartan, pharma sales representative
Daiichi-Sankyo has been cleared of any wrongdoing in relation to the ABPI Code after one of its representatives was accused …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
September 14, 2026
